<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02390258</url>
  </required_header>
  <id_info>
    <org_study_id>XEN-D0103-CL-01</org_study_id>
    <nct_id>NCT02390258</nct_id>
  </id_info>
  <brief_title>Fed-Fasted, Single and Multiple Ascending Dose Trial of XEN-D0103</brief_title>
  <official_title>A Single Centre, Randomised, Double-blind, Placebo-controlled, Fed-fasted, Single and Multiple Ascending Dose Trial of XEN-D0103 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xention Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xention Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an evaluation of the safety and tolerability of XEN-D0103 in healthy subjects.
      Part 1 assesses the safety, tolerability and blood levels of the ascending single doses of
      XEN-D0103. Blood levels of XEN-D0103 will be assessed when administered with food and also
      without food in Part 2. The safety, tolerability and blood levels of XEN-D0103 will be
      assessed following dosing for 10 days in Part 3.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Part 1: 13 days; Part 2: 13 days; Part 3: 22 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) of XEN-D0103 following single and multiple dose administration</measure>
    <time_frame>Part 1: 13 days; Part 3: 22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food effect on AUC of XEN-D0103</measure>
    <time_frame>13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QTcF with XEN-D0103 and with placebo</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Part 1: Single Ascending Dose - Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects (6 receiving 10mg XEN-D0103, 2 receiving placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Single Ascending Dose - Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects (6 receiving 30mg XEN-D0103, 2 receiving placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Single Ascending Dose - Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects (6 receiving 60mg XEN-D0103, 2 receiving placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Single Ascending Dose - Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects (6 receiving 120mg XEN-D0103, 2 receiving placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Single Ascending Dose - Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects (6 receiving 200mg XEN-D0103, 2 receiving placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Fed-Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>17 subjects receiving 200mg XEN-D0103 with either a high fat meal or following an overnight fast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Multiple Ascending Dose - Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects (8 receiving 30mg XEN-D0103 twice daily, 2 receiving placebo twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Multiple Ascending Dose - Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects (8 receiving 60mg XEN-D0103 twice daily, 2 receiving placebo twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Multiple Ascending Dose - Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects (8 receiving 150mg XEN-D0103 once daily, 2 receiving placebo once daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10mg XEN-D0103</intervention_name>
    <arm_group_label>Part 1: Single Ascending Dose - Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Part 1: Single Ascending Dose - Cohort 1</arm_group_label>
    <arm_group_label>Part 1: Single Ascending Dose - Cohort 2</arm_group_label>
    <arm_group_label>Part 1: Single Ascending Dose - Cohort 3</arm_group_label>
    <arm_group_label>Part 1: Single Ascending Dose - Cohort 4</arm_group_label>
    <arm_group_label>Part 1: Single Ascending Dose - Cohort 5</arm_group_label>
    <arm_group_label>Part 3: Multiple Ascending Dose - Cohort 1</arm_group_label>
    <arm_group_label>Part 3: Multiple Ascending Dose - Cohort 2</arm_group_label>
    <arm_group_label>Part 3: Multiple Ascending Dose - Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30mg XEN-D0103</intervention_name>
    <arm_group_label>Part 1: Single Ascending Dose - Cohort 2</arm_group_label>
    <arm_group_label>Part 3: Multiple Ascending Dose - Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>60mg XEN-D0103</intervention_name>
    <arm_group_label>Part 1: Single Ascending Dose - Cohort 3</arm_group_label>
    <arm_group_label>Part 3: Multiple Ascending Dose - Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>120mg XEN-D0103</intervention_name>
    <arm_group_label>Part 1: Single Ascending Dose - Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200mg XEN-D0103</intervention_name>
    <arm_group_label>Part 1: Single Ascending Dose - Cohort 5</arm_group_label>
    <arm_group_label>Part 2: Fed-Fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>150mg XEN-D0103</intervention_name>
    <arm_group_label>Part 3: Multiple Ascending Dose - Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Parts 1 and 3 healthy, male subjects aged 18 to 45 years, inclusive. For Part 2
             healthy, male and female subjects aged 45 to 65 years, inclusive.

          -  Females must be of non-childbearing potential

        Exclusion Criteria:

          -  Subject has a known heart disease.

          -  Subject has any of QTcF &gt; 450 msec, PR ≥ 210 msec or QRS ≥ 120 msec at screening
             (determined from median of three readings).

          -  For Part 1 only: subject has resting heart rate outside of the range 45 to 80 beats
             per minute (bpm) at screening (determined from median of three readings).

          -  Subject has any other condition which, in the investigator's opinion will interfere
             with the trial.

          -  Subject has a systolic blood pressure (BP) &lt;80 or &gt;160 mmHg at screening or a
             diastolic BP &gt;90 or &lt;45 mmHg at screening.

          -  Subject has a clinically significant abnormal laboratory test result at screening.

          -  Female subject who is pregnant or breast feeding and female subjects of childbearing
             potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ICON Development Solutions</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

